Pharm-Olam International Announces That It Has Been Appointed as Contract Research Organization for Global Phase 2 Lymphoma Study
Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is pleased to announce that is has been selected as the Contract Research Organization for Infinity Pharmaceuticals, Inc. for the conduct of Infinity’s FRESCO study, a Phase II clinical trial of an investigational medicine for the treatment of relapsed/refractory follicular lymphoma.
“We are extremely pleased to continue our collaboration with Infinity,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer (USA). Suri added, “The Infinity team required a fast, flexible solution to provide a timely quality deliverable. It is a credit to our project teams that Infinity has decided to continue with Pharm-Olam as a part of its future clinical plans.”
Infinity previously partnered with Pharm-Olam for Clinical, Project Management, Medical Monitoring, Data Management, and Regulatory Services for DYNAMO™, a Phase II study for patients with refractory indolent non-Hodgkin’s lymphoma (iNHL).
Both companies share a commitment to advancing new investigational medicines for people with difficult-to-treat diseases. Pharm-Olam provided the speed and flexibility required for Infinity’s DYNAMO study and rapidly identified and engaged with its network of specialist sites and organizations to meet enrollment goals. With extensive study and functional outsourcing experience, Pharm-Olam’s established competencies, global staff network and flat organizational structure proved a strong match for Infinity.
“In working with Pharm-Olam on the DYNAMO study, Pharm-Olam assigned Infinity a team of very capable individuals who complement one another in their unique strengths. We are pleased that they are now also supporting our Phase II FRESCO study,” stated Ross Pettit, Infinity’s Senior Vice President, Development Operations. “Pharm-Olam not only has deep expertise but also puts exceptional energy and enthusiasm into the work that they do. They have played a key role in helping Infinity to execute and advance its lead clinical program, and we are pleased to continue our collaboration.”
For more information about Pharm-Olam and its global Phase I-IV clinical research solutions, contact firstname.lastname@example.org .
About Pharm-Olam International Group
Pharm-Olam International is a multi-national Contract Research Organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com .
Mark Eberhardt, 713-559-7350
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DE-INCYTE21.10.2018 12:47 | pressemeddelelse
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
SERVIER21.10.2018 11:12 | pressemeddelelse
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum